Ubidecarenone (Ubidecarenonum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Antihypoxants and antioxidants

Included in the formulation
  • Valeocor-Q10®
    pills inwards 
    FARMASOFT NPK, LLC     Russia
  • Kudevita®
    capsules inwards 
    PIK-PHARMA, LLC     Russia
  • Coudesan®
    drops inwards 
    VNESHTORG PHARMA, LLC     Russia
  • Kudesan® for children
    pills inwards 
    RUSFIK, LLC     Russia
    • АТХ:

    C.01.E.X   Other combination drugs for the treatment of heart disease

    C.01.E.X.09   Ubidecarenone

    Pharmacodynamics:

    Component of the respiratory chain, the carrier of hydrogen ions. An increase in the content of prostacyclin and a decrease in the amount of thromboxane in the blood. Pharmacological effects: antioxidant, membrane stabilizing, cardioprotective, adaptogenic, immunostimulating.

    Pharmacokinetics:

    Experimental studies in animals have shown that after ingestion the drug is rapidly absorbed, the maximum concentration in the plasma is achieved after 1 hour after administration. Bioavailability of the drug is 20%. Half-life is 2 hours. The drug is excreted in the urine in an unchanged form and in the form of metabolites.

    Indications:

    IHD, incl. myocardial infarction (acute, subacute period, rehabilitative therapy), heart failure; increase physical fitness and adaptation to increased stress in athletes (metabolic therapy).

    ICD-10

    XIII.M70-M79.M70.9   Soft tissue diseases associated with exercise, overload and pressure, unspecified

    XIII.M70-M79.M70.8   Other soft tissue diseases associated with exercise, overload and pressure

    XIII.M70-M79.M70   Diseases of soft tissues associated with exercise, overload and pressure

    IX.I20-I25.I21   Acute myocardial infarction

    IX.I20-I25.I25.90   Chronic ischemic heart disease, unspecified with hypertension

    IX.I20-I25.I25.9   Chronic ischemic heart disease, unspecified

    IX.I20-I25.I25   Chronic ischemic heart disease

    IX.I30-I52.I50.9   Heart failure, unspecified

    IX.I30-I52.I50   Heart failure

    IX.I26-I28.I27.9   Pulmonary heart disease, unspecified

    Contraindications:

    Hypersensitivity.

    Carefully:

    Pregnancy, breast-feeding, children under 18 years.

    Pregnancy and lactation:

    The category of FDA recommendations is not defined.

    Adequate and well-controlled studies in humans and animals have not been conducted. No information on the penetration into breast milk.

    Dosing and Administration:

    Inside, regardless of food intake, 0,03-0,045 g 3 times a day, the course of treatment 1-3 months. If necessary, repeat the course.

    Athletes in the preparatory period or during the competition - 0,045-0,075 g 2-3 times a day for 7-10 days.

    Side effects:

    Nausea, diarrhea.

    Overdose:

    Not described.

    Interaction:

    Simultaneous use with atenolol, warfarin, metaprolol, propranolol can lead to a decrease in the concentration of ubidecarenone in the blood plasma.

    Ubidekarenon can potentiate the action of diltiazem, metoprolol, enalapril.

    Special instructions:

    Increased physical performance on the background of admission was noted.

    Instructions
    Up